Day: January 20, 2026

SAG Unveils LiquidMate O: A Breakthrough UHF RFID Tagging Solution for Item-Level Traceability of Liquid-Filled Injectable Medications

Patent-pending direct-on-vial RFID label enables DSCSA-ready traceability across pharmaceutical manufacturing and hospital workflowsTAICHUNG, Jan. 20, 2026 /PRNewswire/ -- SAG today...

SAG Unveils LiquidMate O: A Breakthrough UHF RFID Tagging Solution for Item-Level Traceability of Liquid-Filled Injectable Medications

Patent-pending direct-on-vial RFID label enables DSCSA-ready traceability across pharmaceutical manufacturing and hospital workflowsTAICHUNG, Jan. 20, 2026 /PRNewswire/ -- SAG today...

SAG Unveils LiquidMate O: A Breakthrough UHF RFID Tagging Solution for Item-Level Traceability of Liquid-Filled Injectable Medications

Patent-pending direct-on-vial RFID label enables DSCSA-ready traceability across pharmaceutical manufacturing and hospital workflowsTAICHUNG, Jan. 20, 2026 /PRNewswire/ -- SAG today...

Patient Engagement Solutions Market to Grow at a Robust CAGR of 21.25%, Crossing USD 229.5 Billion by 2035 | Vantage Market Research

NEW YORK  , Jan. 20, 2026 /PRNewswire/ -- The Global Patient Engagement Solutions Market is undergoing a profound transformation as healthcare systems worldwide...

Patient Engagement Solutions Market to Grow at a Robust CAGR of 21.25%, Crossing USD 229.5 Billion by 2035 | Vantage Market Research

NEW YORK  , Jan. 20, 2026 /PRNewswire/ -- The Global Patient Engagement Solutions Market is undergoing a profound transformation as healthcare systems worldwide...

Patient Engagement Solutions Market to Grow at a Robust CAGR of 21.25%, Crossing USD 229.5 Billion by 2035 | Vantage Market Research

NEW YORK  , Jan. 20, 2026 /PRNewswire/ -- The Global Patient Engagement Solutions Market is undergoing a profound transformation as healthcare systems worldwide...

Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis

The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan...

Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis

The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan...

Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis

The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan...

error: Content is protected !!